Johnson & Johnson (JNJ)
(Real Time Quote from BATS)
$160.44 USD
+0.75 (0.47%)
Updated Oct 9, 2024 11:22 AM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
Price, Consensus and EPS Surprise
JNJ 160.44 +0.75(0.47%)
Will JNJ be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for JNJ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for JNJ
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Intuitive Surgical Stock Declines 0.7% in a Month: Is It Losing Steam?
JNJ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Invesco Large Cap Value ETF (PWV) a Strong ETF Right Now?
Should Investors Consider High Yield Dividend Stocks?
Analysts Estimate Johnson & Johnson (JNJ) to Report a Decline in Earnings: What to Look Out for
Other News for JNJ
The Quality Dividend ETF, XDU:CA, That's Crushing SCHD In 2024
U.S. Bankruptcies YTD Near Pandemic High After 59 Filings In September
J&J closes V-Wave deal, to incur IPR&D charge of $600M in Q4
On drug prices, Harris pushes for cuts, Trump offers few specifics, NYTimes say
Should Investors Consider High Yield Dividend Stocks?